Abstract
More than 20 years after the identification of the sigma receptors as a unique binding site in the brain and in the peripheral organs, several questions regarding this receptor are still open. Only one of the subtypes of the receptor has been cloned to date, but the endogenous ligand still remains unknown, and the possible association of the receptor with a conventional second messenger system is controversial. From the very beginning, the sigma receptors were associated with various central nervous system disorders such as schizophrenia or movement disorders. Today, after hundreds of papers dealing with the importance of sigma receptors in brain function, it is widely accepted that sigma receptors represent a new and different avenue in the possible pharmacological treatment of several brain-related disorders. In this review, what is known about the biology of the sigma receptor regarding its putative structure and its distribution in the central nervous system is summarized first. The role of sigma receptors regulating cellular functions and other neurotransmitter systems is also addressed, as well as a short overview of the possible endogenous ligands. Finally, although no specific sigma ligand has reached the market, different pharmacological approaches to the alleviation and treatment of several central nervous system disorders and deficits, including schizophrenia, pain, memory deficits, etc., are discussed, with an overview of different compounds and their potential therapeutic use.
Similar content being viewed by others
References
Akunne HC, Zoski KT, Whetzel SZ, Cordon JJ, Brandon RM, Roman F, Pugsley TA (2001) Neuropharmacological profile of a selective sigma ligand igmesine: a potential antidepressant. Neuropharmacology 41:138–149
Alonso G, Phan V-L, Guillemain I, Saunier M, Legrand A, Anoal M, Maurice T (2000) Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system. Neuroscience 97:155–170
Ault DT, Werling LL (1997) Differential modulation of NMDA-stimulated [3H]dopamine release from rat striatum by neuropeptide Y and sigma receptor ligands. Brain Res 760:210–217
Ault DT, Werling LL (1998) Neuropeptide Y-mediated enhancement of NMDA-stimulated [3H]dopamine release from rat prefrontal cortex is reversed by sigma1 receptor antagonists. Schizophr Res 31:27–36
Aydar E, Palmer CP, Klyachko VA, Jackson MB (2002) The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34:399–410
Bartoszky GD, Bender HM, Hellman J, Schnorr C, Seyfred CA (1996) EMD 57445: a selective sigma ligand with the profile of an atypical neuroleptic. CNS Drug Rev 2:175–194
Basile AS, Paul I, Mirchevich A, Kuijpers G, de Costa B (1992) Modulation of (+)-[3H]pentazocine binding to guinea pig cerebellum by divalent ions. Mol Pharmacol 42:882–889
Beart PM, O’Shea RD, Manallack DT (1989) Regulation of sigma-receptors: high- and low-affinity agonist states GTP shifts and up-regulation by rimcazole and 13-Di(2-tolyl) guanidine. J Neurochem 53:779–788
Bergeron R, Debonnel G (1997) Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors. Psychopharmacology 129:215–224
Bouchard P, Quirion R (1997) [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma 1 and sigma 2 receptor subtypes. Neuroscience 76:467–477
Bouchard P, Maurice T, St-Pierre S, Privat A, Quirion R (1997)Neuropeptide Y and the calcitonin gene-related peptide attenuate learningimpairments induced by MK-801 via a sigma receptor-related mechanism. EurJ Neurosci 9:2142–2152
Bowen WD (1994) Interaction of sigma receptors with signal transduction pathways and effects on second messengers. In: Itzhak Y (ed) Sigma receptors. Academic, San Diego, pp 139–170
Bowen WD (2000) Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 74:211–218
Bowen WD, Kirschner BN, Newman AH, Rice KC (1988) Sigma receptors negatively modulate agonist-stimulated phosphoinositide metabolism in rat brain. Eur J Pharmacol 177:111–118
Bowen WD, Walker JM, de Costa BR, Wu R, Tolentino PJ, Finn D, Rothman RB, Rice KC (1992) Characterization of the enantiomers of cis-N-[2-(34-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)cyclohexylamine (BD737 and BD738): novel compounds with high affinity selectivity and biological efficacy at sigma receptors. J Pharmacol Exp Ther 262:32–40
Bowen WD, de Costa BR, Hellewell SB, Walker JM, Rice KC (1993) [3H](+)-Pentazocine: a potent and highly selective benzomorphan-based probe for sigma-1 receptors. Mol Neuropharmacol 3:117–126
Bowen WD, Bertha CM, Vilner BJ, Rice KC (1995a) CB-64D and CB-184: ligands with high sigma-2 receptor affinity and subtype selectivity. Eur J Pharmacol 278:257–260
Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jacobson AE (1995b) Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. Eur J Pharmacol 279:R1–R3
Bowen WD, Vilner BJ, Bandarage UK, Kuehne ME (1996) Ibogaine and ibogamine modulate intracellular calcium levels via interaction with sigma-2 receptors. Soc Neurosci Abstr 22(7875):2006
Bowlby MR (1993) Pregnenolone sulphate potentiation of N-methyl-d-aspartate receptor channels in hippocampal neurons. Mol Pharmacol 43:813–819
Brady KT, Balster RL, May EL (1982) Stereoisomers of N-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 215:178–180
Chaki S, Tanaka M, Muramatsu M, Otomo S (1994) NE-100, a novel potent sigma ligand preferentially binds to sigma 1 binding sites in guinea pig brain. Eur J Pharmacol 251:R1–R2
Chaki S, Okuyama S, Ogawa S, Tomisawa K (1998) Regulation of NMDA-induced [3H]dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochem Int 33:29–34
Chien C-C, Pasternak GW (1993) Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid σ1 system. Eur J Pharmacol 250:R7–R8
Chien C-C, Pasternak GW (1994) Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther 271:1583–1590
Chien C-C, Pasternak GW (1995) Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett 190:137–139
Church J, Fletcher EJ (1995) Blockade by sigma site ligands of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurons. Br J Pharmacol 116:2801–2810
Clissold DB, Pontecorvo MJ, Jones BE, Abreu ME, Karbon EW, Erikson RH, Natalie KJ Jr, Borosky S, Hartman T, Mansbach RS, Balster RL, Ferkany JW, Enna SJ (1993) NPC 16377: a potent and selective σ-ligand. II. Behavioral and neuroprotective profile. J Pharmacol Exp Ther 265:876–886
Connick JH, Hanlon G, Roberts J, France L, Fox PK, Nicholson CD (1992) Multiple sigma binding sites in guinea-pig and rat brain membranes: G-protein interactions. Br J Pharmacol 107:726–731
de Costa BR, He X-S (1994) Structure–activity relationships and evolution of sigma receptor ligands (1976-present). In: Itzhak Y (ed) Sigma receptors. Academic, San Diego, pp 45–111
Couture S, Debonnel G (1998) Modulation of the neuronal response to N-methyl-d-aspartate by selective sigma 2 ligands. Synapse 29:62–71
Craviso GL, Musacchio JM (1983) High affinity dextromethorphan binding sites in guinea pig. II. Competition experiments. Mol Pharmacol 23:629–640
Crawford KW, Coop A, Bowen WD (2002) σ2 Receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol 443:207–209
Cutts JM, de Costa BR, Bowen WD (1993) Sigma ligands have reduced ability to inhibit the muscarinic phosphoinositide response in cells deficient in sigma-1 receptors. In: Harris LS (ed) Problems of Drug Dependence 1992. Proceedings of the 54th annual scientific meeting, National Institute of Drug Abuse Research Monograph 132, US Government Printing Office, p 403
Debonnel G (1993) Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J Psychiatry Neurosci 18:157–172
Debonnel G, deMontigny C (1996) Modulation of NMDA and dopaminergic neurotransmission by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 58:721–734
DeHaven-Hudkins DL, Fleissner LC (1992) Competitive interactions at [3H]-13-(2-tolyl)guanidine (DTG)-defined sigma recognition sites in guinea pig brain. Life Sci 50:PL65–PL70
DeHaven-Hudkins DL, Fleissner LC, Ford-Rice FY (1992) Characterization of the binding of [3H](+)-pentazocine to sigma recognition sites in guinea pig brain. Eur J Pharmacol 227:371–378
Derbez AE, Mode RM, Werling LL (2002) σ2-Receptor regulation of dopamine transporter via activation of protein kinase C. J Pharmacol Exp Ther 301:306–314
Dumont M, Lemaire S (1991) Interaction of 1,3-di(2-[5-3H]tolyl)guanidine with σ-2 binding sites in rat heart membrane preparations. Eur J Pharmacol 209:245–248
Earley B, Burke M, Leonard BE, Gouret CJ, Junien JL (1991) Evidence for an anti-amnesic effect of JO 1784 in the rat: a potent and selective ligand for the sigma receptor. Brain Res 546:282–286
Ela C, Barg J, Vogel Z, Hasin Y, Eliam Y (1994) Sigma receptor ligands modulate contractility Ca++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 269:1300–1309
Ela C, Hasin Y, Eilam Y (1996) Apparent desensitization of a sigma receptor sub-population in neonatal rat cardiac myocytes by pre-treatment with sigma receptor ligands. Eur J Pharmacol 295:275–280
Ericson H, Ross SB (1992) Subchronic treatment of rats with remoxipride fails to modify σ binding sites in the brain. Eur J Pharmacol 226:157–161
Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ (1995) Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15:2453–2461
Flood JF, Morley JE, Roberts E (1992) Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci U S A 89:1567–1571
Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A (1997) Open clinical trial of the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 132:82–88
Gebreselassie D, Bowen WD (2002) σ2 Receptors are components of sphingolipid/cholesterol-rich membrane rafts. Soc Neurosci Abstr 235.20
Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994) BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37–40
Ghelardini C, Galeotti N, Bartolini A (2000) Pharmacological identification of SM-21, the novel sigma(2) antagonist. Pharmacol Biochem Behav 67:659–662
Gillgan PJ, Tam SW (1994) Sigma receptor ligands: potential drugs for the treatment of CNS disorders? Drug News Perspect 7:13–18
Gonzalez-Alvear GM, Werling LL (1995) Sigma1 receptors in rat striatum regulate NMDA-stimulated [3H]dopamine release via a presynaptic mechanism. Eur J Pharmacol 294:713–719
Gore AC (2001) Gonadotropin-releasing hormone neurons NMDA receptors and their regulation by steroid hormones across the reproductive life cycle. Brain Res Rev 37:235–248
Gronier B, Debonnel G (1999) Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol 368:183–196
Grunder G, Muller MJ, Andreas J, Heydari N, Wetzel H, Schlosser R, Schlegel S, Nickel O, Eissner D, Benkert O (1999) Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445: a putative atypical antipsychotic. Psychopharmacology 146:81–86
Guitart X, Farré AJ (1998) The effect of E-5842, a σ receptor ligand and potential atypical antipsychotic on Fos expression in rat forebrain. Eur J Pharmacol 363:127–130
Guitart X, Codony X, Ballarín M, Dordal A, Farré AJ (1998) E-5842: a new potent and preferential sigma ligand: preclinical pharmacological profile. CNS Drug Rev 4:201–224
Guitart X, Méndez R, Ovalle S, Andreu F, Carceller A, Farré AJ, Zamanillo D (2000) Regulation of ionotropic glutamate receptor subunits in different rat brain areas by a preferential sigma1 receptor ligand and potential atypical antipsychotic. Neuropsychopharmacology 23:539–546
Gundlach AL, Largent BL, Snyder SH (1986) Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)-piperidine. J Neurosci 6:642–647
Haertzen CA (1970) Subjective effects of narcotic antagonists cyclazocine and nalorphine on the addiction research center inventory (ARCI). Psychopharmacologia 18:366–377
Hanner M, Moebius FF, Weber F, Grabner M, Striessnig J, Glossmann (1995) Phenylalkylamine Ca2+ antagonist binding protein. Molecular cloning, tissue distribution and heterologous expression. J Biol Chem 271:7551–7557
Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H (1996) Purification molecular cloning and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A 93:8072–8077
Hayashi T, Su T-P (2001) Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci U S A 98:491–496
Hayashi T, Kagaya A, Takebayashi M, Shimizu M, Uchitomi Y, Motohashi N, Yamawaki S (1995) Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-d-aspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther 275:207–214
Hayashi T, Maurice T, Su TP (2000) Ca (2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca (2+)concentration. J Pharmacol Exp Ther 293:788–798
Heading C (2001) Siramesine. Curr Opin Investig Drugs 2:266–270
Hellewell SB, Bowen WD (1990) A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that in guinea pig brain. Brain Res 527:244–253
Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD (1994) Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol Mol Pharmacol Sect 268:9–18
Hong W, Werling LL (2000) Evidence that the sigma(1) receptor is not directly coupled to G proteins. Eur J Pharmacol 408:117–125
Hong W, Werling LL (2001) Lack of effects by s ligands on neuropeptide Y-induced G-protein activation in rat hippocampus and cerebellum. Brain Res 901:208–218
Inoue A, Sugita S, Shoji H, Ichimoto H, Hide I, Nakata Y (2000) Repeated haloperidol treatment decreases σ1 receptor binding but does not affect its mRNA levels in the guinea pig or rat brain. Eur J Pharmacol 401:307–316
Ishiguro H, Ohtsuki T, Toru M, Itokawa M, Aoki J, Shibuya H, Kurumaji A, Okubo Y, Iwawaki A, Ota K, Shimizu H, Hamaguchi H, Arinami T (1998) Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia. Neurosci Lett 257:45–48
Itzhak Y (1993) Repeated methamphetamine-treatment alters brain sigma receptors. Eur J Pharmacol 230:243–244
Itzhak Y (1994) Multiple sigma binding sites in the brain. In: Itzhak Y (ed) Sigma receptors. Academic, San Diego, pp 113–137
Iwamoto ET (1981) Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J Pharmacol Exp Ther 217:451–460
Izenwasser S, Thompson-Montgomery D, Deben SE, Chowdhury IN, Werling LL (1998) Modulation of amphetamine-stimulated (transporter-mediated) dopamine release in vitro by σ2 receptor agonists and antagonists. Eur J Pharmacol 346:189–196
Jansen KLR, Faull RLM, Dragunow M, Leslie RA (1991) Autoradiographic distribution of sigma receptors in human neocortex hippocampus basal ganglia cerebellum pineal and pituitary glands. Brain Res 559:172–177
Jansen KL, Elliot M, Leslie RA (1992) Sigma receptors in rat brain and testes show similar reductions in response to chronic haloperidol. Eur J Pharmacol 214:281–283
Jonas EA, Kaczmarek LK (1996) Regulation of potassium channels by protein kinases. Curr Opin Neurobiol 6:318–323
Karasawa J, Yamamoto H, Yamamoto T, Sagi N, Horikomi K, Sora I (2002) MS-377, a selective sigma receptor ligand indirectly blocks the action of PCP in the N-methyl-d-aspartate receptor ion-channel complex in primary cultured rat neuronal cells. Life Sci 70:1631–1642
Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V (1996) Cloning and functional expression of the human type 1 sigma receptor (hSigmaR 1). Biochem Biophys Res Commun 229:553–558
King MA, Pan Y-X, Mei J, Chang A, Xu J, Pasternak GW (1997) Enhanced kappa opioid analgesia by antisense targeting the σ1 receptor. Eur J Pharmacol 331:R5–R7
Klein MD, Musacchio JM (1989) High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents. J Pharmacol Exp Ther 251:207–215
Klein MD, Musacchio JM (1994) Effects of cytochrome P450 ligands on the binding of [3H]dextrometorphan and sigma ligands to guinea-pig brain. In: Itzhak Y (ed) Sigma receptors. Academic, San Diego, pp 243–262
Klette KL, DeCoster MA, Moreton JE, Tortella FC (1995) Role of calcium in sigma-mediated neuroprotection in rat primary cortical neurons. Brain Res 704:31–41
Klette KL, Lin Y, Clapp LE, DeCoster MA, Moreton JE, Tortella FC (1997) Neuroprotective sigma ligands attenuate NMDA and trans-ACPD-induced calcium signaling in rat primary neurons. Brain Res 756:231–240
Koe BK, Burkhart CA, Lebel LA (1989) (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)-piperidine binding to σ receptors in mouse brain in vivo. Eur J Pharmacol 161:263–266
Lambert JJ, Harney SC, Belelli D, Peters JA (2001) Neurosteroid modulation of recombinant and synaptic GABAA receptors. Int Rev Neurobiol 46:177–205
Langa F, Codony X, Tovar V, Lavado A, Gimenez E, Cozar P, Cantero M, Dordal A, Hernández E, Pérez R, Monroy X, Zamanillo D, Guitart X, Montoliu L (2003) Generation and phenotypic analysis of sigma receptor type I (σ1) knockout mice. Eur J Neurosci 18:2188–2196
Largent BL, Gundlach AL, Snyder SH (1986) Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047 (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]-piperidine. J Pharmacol Exp Ther 238:739–748
Leitner ML, Hohmann AG, Patrick SL, Walker JM (1994) Regional variation in the ratio of sigma 1 to sigma 2 binding in rat brain. Eur J Pharmacol 259:65–69
Lupardus PJ, Wilke RA, Aydar E, Palmer CP, Chen Y, Ruoho AE, Jackson MB (2000) Membrane-delimited coupling between sigma receptors and K+ channels in rat neurohypophysial terminals requires neither G-protein nor ATP. J Physiol 526:527–539
Martin WR, Eades CE, Thompson JA, Huppler RE (1976) The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532
Maruo J, Yoshida A, Shimohira I, Matsuno K, Mita S, Ueda H (2000) Binding of [35S]GTPgammaS stimulated by (+)-pentazocine sigma receptor agonist is abundant in the guinea pig spleen. Life Sci 67:599–603
Matsumoto RR, Mack AL (2001) (±)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur J Pharmacol 417:R1–R2
Matsumoto RR, Pouw B (2000) Correlation between neuroleptic binding to sigma(1) and sigma(2) receptors and acute dystonic reactions. Eur J Pharmacol 401:155–160
Matsumoto RR, Hemstreet MK, Lai NL, Thurkauf A, de Costa BR, Rice KC, Hellewell SB, Bowen WB, Walker JM (1990) Drug specificity of pharmacological dystonia. Pharmacol Biochem Behav 36:151–155
Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, de Costa BR (1995) Characterization of two novel σ receptor ligands: antidystonic effects in rats suggests s receptor antagonism. Eur J Pharmacol 365:35–38
Matsumoto RR, McCraken KA, Friedman MJ, Pouw B, de Costa BR, Bowen WD (2001) Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma 1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 419:163–174
Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD (2002) Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 42:1043–1055
Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ (2003) Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 469:1–12
Matsuno K, Matsunaga K, Senda T, Mita S (1993) Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex. J Pharmacol Exp Ther 265:851–859
Matsuno K, Senda T, Matsunaga K, Mita S (1994) Ameliorating effects of sigma receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system. Eur J Pharmacol 261:43–51
Matsuno K, Senda T, Kobayashi T, Mita S (1995) Involvement of sigma 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res 690:200–206
Matsuno K, Kobayashi T, Tanaka MK, Mita S (1996a) Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 286:213–217
Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S (1996b) Binding properties of SA4503: a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 306:271–279
Matsuno K, Senda T, Kobayashi T, Okamoto K, Nakata K, Mita S (1997) SA4503: a novel cognitive enhancer with sigma1 receptor agonistic properties. Behav Brain Res 83:221–224
Maurice T, Lockhart BP (1997) Neuroprotective and anti-amnesic potentials of sigma receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 21:69–102
Maurice T, Su TP, Parish DW, Nabeshima T, Privat A (1994) PRE-084: a sigma selective PCP derivative attenuates MK-801-induced impairment of learning in mice. Pharmacol Biochem Behav 49:859–869
Maurice T, Roman FJ, Privat A (1996) Modulation by neurosteroids of the in vivo (+)-[3H]SKF 10,047 binding to sigma1 receptors in the mouse forebrain. J Neurosci Res 46:734–743
Maurice T, Junien JL, Privat A (1997) Dehydroepiandrosterone sulphate attenuates dizocilpine-induced learning impairment in mice via σ1-receptors. Behav Brain Res 83:159–164
Maurice T, Su TP, Privat A (1998) Sigma1 (σ1) receptor agonists and neurosteroids attenuate β25–35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 83:413–428
Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nameshima T (1999) Neuroactive steroids as endogenous effectors for the sigma1 (σ1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 81:125–155
Maurice T, Urani A, Phan V-L, Romieu P (2001) The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Rev 37:116–132
Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR (2002) Sigma1(σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 26:499–527
McCann DJ, Su TP (1990) Haloperidol-sensitive (+)[3H]SKF 10,047 binding sites (sigma sites) exhibit a unique distribution in rat brain subcellular fractions. Eur J Pharmacol 188:211–218
McCann DJ, Su T-P (1991) Solubilization and characterization of haloperidol-sensitive (+)-[3H]SKF 10,047 binding sites (sigma sites) from rat liver membranes. J Pharmacol Exp Ther 257:547–554
McCann DJ, Weissman AD, Su TP (1994) Sigma-1 and sigma-2 sites in rat brain: comparison of regional ontogenic and subcellular patterns. Synapse 17:182–189
McCraken KA, Bowen WD, Matsumoto RR (1999) Novel σ receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur J Pharmacol 365:35–38
McLean S, Weber E (1988) Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 25:259–269
Mei J, Pasternak GW (2001) Molecular cloning and pharmacological characterization of the rat sigma1 receptor. Biochem Pharmacol 62:349–355
Mei J, Pasternak GW (2002) σ1 Receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther 300:1070–1074
Mendelsohn LG, Kalra V, Johnson BG, Kerchner GA (1985) Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor. J Pharmacol Exp Ther 233:597–602
Menkel M, Terry P, Pontecorvo M, Katz JL, Witkin JM (1991) Selective sigma ligands block stimulant effects of cocaine. Eur J Pharmacol 201:251–252
Meyer C, Schmieding K, Falkenstein E, Wehling M (1998) Are high-affinity progesterone binding sites(s) from porcine liver microsomes members of the σ receptor family? Eur J Pharmacol 347:293–299
Moebius FF, Striessnig J, Glossmann H (1997a) The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol Sci 18:67–70
Moebius FF, Reiter RJ, Hanner M, Glossmann H (1997b) High affinity of sigma 1-binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8–C7 isomerase. Br J Pharmacol 121:1–6
Moltzen EK, Perregaard J, Meier E (1995) Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. J Med Chem 38:2009–2017
Monnet FP, Debonnel G, Junien JL, deMontigny C (1990) N-methyl-d-aspartate-induced neuronal activity is selectively modulated by sigma receptors. Eur J Pharmacol 179:441–445
Monnet FP, Blier P, Debonnel G, de Montigny C (1992a) Modulation by sigma ligands of N-methyl-d-aspartate-induced [3H]noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 346:32–39
Monnet FP, Debonnel G, de Montigny C (1992b) In vivo electrophysiological evidence for a selective modulation of N-methyl-d-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther 261:123–130
Monnet FP, Debonnel G, Fournier A, de Montigny C (1992c) Neuropeptide Y potentiates selectively the N-methyl-d-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor. J Pharmacol Exp Ther 263:1219–1225
Monnet FP, Fournier A, Debonnel G, de Montigny C (1992d) Neuropeptide Y potentiates selectively the N-methyl-d-aspartate response in the CA3 dorsal hippocampus. I. Involvement of an atypical neuropeptide Y receptor. J Pharmacol Exp Ther 263:1212–1218
Monnet FP, Debonnel G, Bergeron R, Gronier B, de Montigny C (1994) The effects of sigma ligands and of neuropeptide Y on N-methyl-d-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussis toxin. Br J Pharmacol 112:709–715
Monroy X, Romero G, Pérez MP, Farré AJ, Guitart X (2001) Decrease of adenylyl cyclase activity and expression by a sigma1 receptor ligand and putative atypical antipsychotic. Neuroreport 12:1989–1992
Morin-Surun MP, Collin T, Denavit-Saubié M, Baulieu E-E, Monnet FP (1999) Intracellular σ1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc Natl Acad Sci U S A 96:8196–8199
Morio Y, Tanimoto H, Yakushiji T, Morimoto Y (1994) Characterization of the currents induced by sigma ligands in NCB20 neuroblastoma cells. Brain Res 637:190–196
Nestler EJ (2001) Molecular neurobiology of addiction. Am J Addict 10:201–217
Novakova M (1998) Sigma receptors: with special reference to cardiac muscle. Exp Clin Cardiol 3:113–120
Novakova M, Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y (1995) Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol 286:19–30
Novakova M, Ela C, Bowen WD, Hasin Y, Eilam Y (1998) Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Eur J Pharmacol 353:315–327
Nuwayhid SJ, Werling LL (2003) σ1-Receptor agonist-mediated regulation of N-methyl-d-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther 304:364–369
Ohmori O, Shinkai T, Suzuki T, Okano C, Kojima H, Terao T, Nakamura J (2000) Polymorphisms of the sigma(1) receptor gene in schizophrenia: an association study. Am J Med Genet 96:118–122
Ohno M, Watanabe S (1995) Intrahippocampal administration of (+)-SKF 10,047: a sigma ligand reverses MK-801-induced impairment of working memory in rats. Brain Res 684:237–242
Okumura K, Ujike H, Akiyama K, Kuroda S (1996) BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats. J Neural Transm 103:1153–1161
Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, Muramatsu M, Nakazato A, Yamaguchi K, Yoshida M, Otomo S (1993) NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci 53:285–290
Okuyama S, Imagawa Y, Sakagawa T, Nakazato A, Yamaguchi K, Katoh M, Yamada S, Araki H, Otomo S (1994) NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats dogs and monkeys. Life Sci 55:PL133–PL138
Okuyama S, Chaki S, Yae T, Nakazato A, Muramatsu M (1995a) Autoradiographic characterization of binding sites for [3H]NE-100 in guinea pig brain. Life Sci 57:PL333–PL337
Okuyama S, Ogawa S, Nakazato A, Tomizawa K (1995b) Effect of NE-100, a novel sigma receptor ligand on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci Lett 189:60–62
Oshiro Y, Sakurai Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, Uwahodo Y, Miwa T, Nishi T (2000) 3,4-Dihydro-2(1H))-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone and its derivatives. J Med Chem 43:177–189
Pan YX, Mei JF, Xu J, Wan BL, Zuckerman A, Pasternak GW (1998) Cloning and characterization of a σ1 receptor. J Neurochem 70:2279–2285
Pascaud XB, Chovet M, Roze C, Junien JL (1993) Neuropeptide Y and sigma receptor agonists act through a common pathway to stimulate duodenal alkaline secretion in rats. Eur J Pharmacol 231:389–394
Paul IA, Basile AS, Rojas E, Youdim MB, De Costa B, Skolnick P, Pollard HB, Kuijpers GA (1993) Sigma receptors modulate nicotinic receptor function in adrenal chromaffin cells. FASEB J 7:1171–1178
Phan VL, Su TP, Privat A, Maurice T (1999) Modulation of steroidal levels by adrenalectomy/castration and inhibition of neurosteroid synthesis enzymes affect sigma1 receptor-mediated behaviour in mice. Eur J Neurosci 11:2385–2396
Poncelet M, Santucci V, Paul R, Gueudet C, Lavastre S, Guitard J, Steinberg R, Terranova JP, Breliere JC, Soubrie P, Le Fur G (1993) Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A. Neuropharmacology 32:605–615
Prasad PD, Li HW, Fei YJ, Ganapathy ME, Fujita T, Plumley LH, Yang-Feng TL, Leibach FH, Ganapathy V (1998) Exon–intron structure analysis of promoter region and chromosomal localization of the human type 1 sigma receptor gene. J Neurochem 70:443–451
Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su T-P, Tam SW, Taylor DP (1992) A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 13:85–86
Ritz MC, George FR (1993) Cocaine-induced seizures and lethality appear to be associated with distinct central nervous system binding sites. J Pharmacol Exp Ther 264:1333–1343
Roman F, Pascaud X, Duffy O, Vauche D, Martin B, Junien JL (1989a) Neuropeptide Y and peptide YY interact with rat brain sigma and PCP binding sites. Eur J Pharmacol 174:301–302
Roman F, Pascaud X, Chomette G, Bueno L, Junien JL (1989b) Autoradiographic localization of sigma opioid receptors in the gastrointestinal tract of the guinea pig. Gastroenterology 97:76–82
Roman FJ, Pascaud X, Martin B, Vauche D, Junien JL (1990) JO 1784: a potent and selective ligand for rat and mouse brain σ-sites. Eur J Pharmacol 42:439–440
Romero G, Pérez MP, Carceller A, Monroy X, Farré AJ, Guitart X (2000) Changes in phosphoinositide signalling activity and levels of the alpha subunit of Gq/11 protein in rat brain induced by E-5842, a sigma1 receptor ligand and potential atypical antipsychotic. Neurosci Lett 290:189–192
Romieu P, MartinFardon R, Maurice T (2000) Involvement of the sigma 1 receptor in the cocaine-induced conditioned place preference. Neuroreport 11:2885–2888
Ross SB (1991) Heterogeneous binding of σ radioligands in the rat brain and liver: possible relationship to subforms of cytochrome P450. Pharmacol Toxicol 68:293–301
Rothman RB, Reid A, Mahboubi A, Kim CH, De Costa BR, Jacobson AE, Rice KC (1991) Labeling by [3H]13-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands. Mol Pharmacol 39:222–232
Ryan-Moro J, Chien CC, Standifer KM, Pasternak GW (1996) Sigma binding in a human neuroblastoma cell line. Neurochem Res 21:1309–1314
Samovilova NN, Vinogradov VA (1992) Subcellular distribution of (+)-[3H]SKF 10047 binding sites in rat liver. Eur J Pharmacol Mol Pharmacol 225:69–74
Samovilova NN, Nagornaya LV, Vinogradov VA (1988) (+)-[3H]SKF 10,047 binding sites in rat liver. Eur J Pharmacol 147:259–264
Sanchez C, Papp M (2000) The selective sigma(2) ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol 11:117–124
Sanchez C, Arnt J, Costall B, Kelly ME, Meier E, Naylor RJ, Perregaard J (1997) The selective sigma2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents. J Pharmacol Exp Ther 283:1323–1332
Schmidt A, Lebel L, Koe BK, Seeger T, Heym J (1989) Sertraline potently displaces (+)-[3H]3-PPP binding to sigma sites in rat brain. Eur J Pharmacol 165:335–336
Senda T, Matsuno K, Kobayashi T, Nakazawa M, Nakata K, Mita S (1998a) Ameliorative effect of SA4503, a novel cognitive enhancer on the basal forebrain lesion-induced impairment of the spatial learning performance in rats. Pharmacol Biochem Behav 59:129–134
Senda T, Mita S, Kaneda K, Kikuchi M, Akaike A (1998b) Effect of SA4503, a novel sigma1 receptor agonist against glutamate neurotoxicity in cultured rat retinal neurons. Eur J Pharmacol 42:105–111
Seth P, Fei YJ, Huang W, Leibach FH, Ganapathy V (1998) Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem 70:922–931
Sharkey J, Glen KA, Wolfe S, Kuhar MJ (1988) Cocaine binding at sigma receptors. Eur J Pharmacol 149:171–174
Soriani O, Foll FL, Roman F, Monnet FP, Vaudry H, Cazin L (1999) A-current down-modulated by sigma receptor in frog pituitary melanotrope cells through a G protein-dependent pathway. J Pharmacol Exp Ther 289:321–328
Su TP (1993) Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol 7:187–203
Su T-P, Junien JL (1994) Sigma receptors in the central nervous system and the periphery. In: Itzhak Y (ed) Sigma receptors. Academic, San Diego, pp 21–44
Su TP, Hayashi T (2001) Cocaine affects the dynamics of cytoskeletal proteins via sigma(1) receptors. Trends Pharmacol Sci 22:456–458
Su TP, Hayashi T (2003) Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 10:2073–2080
Su T-P, London ED, Jaffe JH (1988) Steroid binding at sigma receptor suggests a link between endocrine nervous and immune systems. Science 240:219–221
Su TP, Wu XZ, Cone EJ, Shukla K, Gund TM, Dodge AL, Parish DW (1991) Sigma compounds derived from phencyclidine: identification of PRE-084, a new selective sigma ligand. J Pharmacol Exp Ther 259:543–550
Takahashi S, Sonehara K, Takagi K, Miwa T, Horikomi K, Mita N, Nagase H, Iizuka K, Sakai K (1999) Pharmacological profile of MS-377, a novel selective antipsychotic agent with selective affinity for sigma receptors. Psychopharmacology 145:295–302
Takahashi S, Miwa T, Horikomi K (2000) Involvement of sigma 1 receptors in methamphetamine-induced behavioural sensitization in rats. Neurosci Lett 289:21–24
Takebayashi M, Hayashi T, Su TP (2002) Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther 303:1227–1237
Tam SW, Mitchell KN (1991) Neuropeptide Y and peptide YY do not bind to brain sigma and phencyclidine binding sites. Eur J Pharmacol 193:121–122
Tam SW, Steinfels GF, Gilligan PJ, Schimdt WK, Cook L (1992) DuP 724 [1-(cyclopropylmethyl)-4-(2′(4″-fluorophenyl)-2′-oxoethyl)-piperidine HBr]: a sigma- and 5-hydroxytryptamine2 receptor antagonist; receptor-binding electrophysiological and neuropharmacological profiles. J Pharmacol Exp Ther 263:1167–1174
Tascedda F, Lovati E, Blom JMC, Muzzioli P, Brunello N, Racagni G, Riva MA (1999) Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 21:211–217
Taylor DP, Dekleva J (1987) The potential antipsychotic BMY 14802 selectively binds to sigma sites. Fed Proc 46:1304
Taylor DP, Eison MS, Moon SL, Schlemmer RF Jr, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG, Braselton JP, Davis HH Jr, Duquette MN, Lamy RC, Libera JM, Ryan E, Wright RN (1993) A role for σ binding in the antipsychotic profile of BMY 14802? In: Souza EB, Clouet D, London E (eds) Sigma PCP and NMDA receptors. NIDA Research Monograph Series, pp 125–157
Tokuyama S, Hirata K, Ide A, Ueda H (1997) Sigma ligands stimulate GTPase activity in mouse prefrontal membranes—evidence for the existence of metabotropic sigma receptor. Neurosci Lett 233:141–144
Tokuyama S, Hirata K, Yoshida A, Maruo J, Matsuno K, Mita S, Ueda H (1999) Selective coupling of mouse brain metabotropic sigma (σ) receptor with recombinant Gi1. Neurosci Lett 268:85–88
Torrence-Campbell C, Bowen WD (1996) Differential solubilization of rat liver sigma 1 and sigma 2 receptors: retention of sigma 2 sites in particulate fraction. Eur J Pharmacol 304:201–210
Tottori K, Miwa T, Uwahodo Y, Yamada S, Nakai M, Oshiro Y, Kikuchi T, Altar CA (2001) Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 41:976–988
Tran TT, de Costa BR, Matsumoto RR (1998) Microinjection of sigma ligands into cranial nerve nuclei produces vacuous chewing in rats. Psychopharmacology 137:191–200
Uchida N, Ujike H, Nakata K, Takaki M, Nomura A, Katsu T, Tanaka Y, Imamura T, Sakai A, Kuroda S (2003) No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies. BMC Psychiatry 3:13
Ujike H, Kanzaki A, Okumura K, Akiyama K, Otsuki S (1992) Sigma antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci 50:PL129–PL134
Ujike H, Kuroda S, Otsuki S (1996) Sigma receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol 296:123–128
Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K (1998) Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 61:247–252
Urani A, Roman FJ, Phan V-L, Su T-P, Maurice T (2001) The antidepressant-like effect induced by σ1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298:1269–1279
Urani A, Romieu P, Portales-Casamar E, Roman FJ, Maurice T (2002) The antidepressant-like effect induced by the sigma1 (σ1) receptor agonist igmesine involves modulation of intracellular calcium mobilization. Psychopharmacology 163:26–35
Van Broekhoven F, Verkes RJ (2003) Neurosteroids in depression: a review. Psychopharmacology 165:97–110
Vaupel DB (1983) Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog. Eur J Pharmacol 92:269–274
Vilner BJ, Bowen WD (1993) Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol Mol Pharmacol Sect 244:199–201
Vilner BJ, Bowen WD (2000) Modulation of cellular calcium by sigma-2 receptors. Release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 292:900–911
Vilner BJ, de Costa BR, Bowen WD (1995) Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 15:117–134
Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42:355–402
Walker JM, Bowen WD, Patrick SL, Williams WE, Mascarella SW, Bai X, Carroll FI (1993) A comparison of (−)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests role of σ2 receptors in motor function. Eur J Pharmacol 231:61–68
Walker JM, Martin WJ, Hohmann AG, Hemstreet MK, Roth JS, Leitner ML, Weiser SD, Patrick SL, Patrick RL, Matsumoto RR (1994) Role of sigma receptors in brain mechanisms of movement. In: Itzhak Y (ed) Sigma receptors. Academic, San Diego, pp 205–224
Weatherspoon JK, Werling LL (1999) Modulation of amphetamine-stimulated [3H]dopamine release from rat pheochromocytoma (PC12) cells by σ type 2 receptors. J Pharmacol Exp Ther 289:278–284
Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JFW (1986) 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci U S A 83:8784–8788
Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB (1991) Selective loss of cerebral cortical sigma but not PCP-binding sites in schizophrenia. Biol Psychiatry 29:41–54
Weissman AD, Su TP, Hedreen JC, London DE (1998) Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 247:29–33
Wickman KD, Clapham DE (1995) G-protein regulation of ion channels. Curr Opin Neurobiol 5:278–285
Wilke RA, Mehta RP, Lupardus PJ, Chen Y, Ruoho AE, Jackson MB (1999a) Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells. J Biol Chem 274:18387–18392
Wilke RA, Lupardus PJ, Grandy DK, Rubinstein M, Low MJ, Jackson MB (1999b) K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors. J Physiol 517:391–406
Yamada M, Nishigami T, Nakasho K, Nishimoto Y, Miyaji H (1994) Relationship between σ-like site and progesterone-binding site of adult male rat liver microsomes. Hepatology 20:1271–1280
Yamamoto H, Miura R, Yamamoto T, Shinohara K, Watanabe M, Okuyama S, Nakazato A, Nukada T (1999) Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Lett 445:19–22
Yoshida K, Takahashi H, Sato K, Higuchi H, Shimizu T (2000) Biperiden hydrochlorate ameliorates dystonia of rats produced by microinjection of sigma ligands into the red nucleus. Pharmacol Biochem Behav 67:497–500
Ytzhak Y (1989) Multiple affinity binding states of the sigma receptor: effect of GTP-binding protein-modifying agents. Mol Pharmacol 36:512–517
Zamanillo D, Andreu F, Ovalle S, Pérez MP, Romero G, Farré AJ, Guitart X (2000) Up-regulation of sigma1 receptor mRNA in rat brain by a putative atypical antipsychotic and sigma receptor ligand. Neurosci Lett 282:169–172
Zamanillo D, Romero G, Dordal A, Pérez P, Vincent L, Méndez R, Andreu F, Hernández E, Pérez R, Monroy X, Ovalle S, Guitart X (2002) Increase of forskolin-stimulated adenylyl cyclase and AP-1 activities by sigma1 receptor expression. FENS Abstr A04617
Zhang H, Cuevas J (2002) Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. J Neurophysiol 87:2867–2879
Zou LB, Yamada K, Sasa M, Nakata Y, Nabeshima T (2000) Effects of sigma1 receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats. Neuropharmacology 39:1617–1627
Zukin SR, Brady KT, Slifer BL, Balster RL (1984) Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res 294:174–177
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guitart, X., Codony, X. & Monroy, X. Sigma receptors: biology and therapeutic potential. Psychopharmacology 174, 301–319 (2004). https://doi.org/10.1007/s00213-004-1920-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-004-1920-9